Reactive X (where X= O, N, S, C, Cl, Br, and I) species nanomedicine
Reactive oxygen, nitrogen, sulfur, carbonyl, chlorine, bromine, and iodine species (RXS,
where X= O, N, S, C, Cl, Br, and I) have important roles in various normal physiological …
where X= O, N, S, C, Cl, Br, and I) have important roles in various normal physiological …
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy
M Links, C Lewis - Drugs, 1999 - Springer
Dose-limiting toxicity secondary to antineoplastic chemotherapy is due to the inability of
cytotoxic drugs to differentiate between normal and malignant cells. The consequences of …
cytotoxic drugs to differentiate between normal and malignant cells. The consequences of …
American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants
ML Hensley, LM Schuchter, C Lindley… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: Because toxicities associated with chemotherapy and radiotherapy
canadversely affect short-and long-term patient quality of life, can limitthe dose and duration …
canadversely affect short-and long-term patient quality of life, can limitthe dose and duration …
[HTML][HTML] Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde's contribution to urothelial dysfunction in vitro
KA Mills, R Chess-Williams, C McDermott - Archives of Toxicology, 2019 - Springer
The clinical use of cyclophosphamide and ifosfamide is limited by a resultant bladder toxicity
which has been attributed to the metabolite acrolein. Another metabolite chloroacetaldehyde …
which has been attributed to the metabolite acrolein. Another metabolite chloroacetaldehyde …
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during …
S Muto, T Matsubara, T Inoue, H Kitamura… - International Journal of …, 2023 - Springer
The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …
the addition of cancer-specific risk factors to those already present for CKD. In this review …
[图书][B] The selection and use of essential medicines: report of the WHO Expert Committee, March 2009 (including the 16th WHO model list of essential medicines and …
World Health Organization - 2009 - apps.who.int
The 17th meeting of the WHO Expert Committee on the Selection and Use of Essential
Medicines was held in Geneva from 23rd to 27th March 2009. The meeting was opened on …
Medicines was held in Geneva from 23rd to 27th March 2009. The meeting was opened on …
Reactive carbonyl species scavengers—novel therapeutic approaches for chronic diseases
SS Davies, LS Zhang - Current pharmacology reports, 2017 - Springer
Abstract Purpose of the Review The purpose of this review is to summarize recent evidence
supporting the use of reactive carbonyl species scavengers in the prevention and treatment …
supporting the use of reactive carbonyl species scavengers in the prevention and treatment …
Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases
N Yilmaz, H Emmungil, S Gucenmez, G Ozen… - The Journal of …, 2015 - jrheum.org
Objective. To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of
mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) …
mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) …
Urological implications of cyclophosphamide and ifosfamide
M Lawson, A Vasilaras, A De Vries… - … journal of urology …, 2008 - Taylor & Francis
Cyclophosphamide and ifosfamide are commonly used cytotoxic medications that are
indicated in a wide range of conditions, both benign and malignant. Complications of their …
indicated in a wide range of conditions, both benign and malignant. Complications of their …
Use of mesna to prevent ifosfamide-induced urotoxicity
LL Siu, MJ Moore - Supportive care in cancer, 1998 - Springer
The purpose of this study was to make evidence-based recommendations regarding the
mode, dosage and schedule of delivery of concomitant mesna (sodium-2 …
mode, dosage and schedule of delivery of concomitant mesna (sodium-2 …